Livzon Pharmaceutical Group Inc. (FRA:LP6)

Market Cap	2.64B -37.0%
Revenue (ttm)	1.38B -8.9%
Net Income	215.75M -22.9%
EPS	0.24 -21.3%
Shares Out	n/a
PE Ratio	12.22
Forward PE	9.84
Dividend	0.18 (6.69%)
Ex-Dividend Date	Jun 16, 2026

Volume	n/a
Open	2.200
Previous Close	2.300
Day's Range	2.200 - 2.200
52-Week Range	2.200 - 4.300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About FRA:LP6

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neuro...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 8,878
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LP6

Financial Performance

In 2025, FRA:LP6's revenue was 12.02 billion, an increase of 1.76% compared to the previous year's 11.81 billion. Earnings were 2.02 billion, a decrease of -1.84%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error